{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T00:18:49Z","timestamp":1793060329330,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000995","name":"Australian National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000995","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Langenbecks Arch Surg"],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Glucagon-Like- Peptide-1 (GLP-1) receptor agonist has an emerging role in obesity management. This meta-analysis and systematic review evaluated the effectiveness of GLP-1 receptor agonists in aiding weight loss and enhancing cardiometabolic health in patients with insufficient weight loss (IWL) or weight regain (WR) after bariatric surgery.\u00a0<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A comprehensive literature search (PubMed, Medline, Embase, Cochrane) was conducted following PRISMA guidelines. Included studies involved adults (\u226518 years) treated with GLP-1 agonists either before or after bariatric surgery. Primary outcomes assessed were weight and BMI changes; secondary outcomes included metabolic improvements and adverse effects.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results\u00a0<\/jats:title>\n                    <jats:p>19 studies were included in the systematic review and meta-analysis. All included study involves at least one type of GLP-1 agonist for IWL or WR after bariatric surgery with duration of intervention between 3 months to 24 months. All studies showed significant weight and BMI changes from baseline after initiation of different types of GLP-1 agonist, with effects proportionate to length of intervention. Semaglutide outperformed liraglutide in achieving \u226510% and \u226515% weight loss post-surgery. Tirzepatide, a newer GLP-1\/GIP agonist, showed even greater weight loss compared to semaglutide over 6 months. A systematic review of 6 studies on the metabolic effects of GLP-1 receptor agonists (RA) post-bariatric surgery highlighted significant improvements in glycemic control, blood pressure, cholesterol levels, and liver function. Adverse effects were mostly mild gastrointestinal symptoms with no severe events reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>GLP-1 agonists have emerged as a promising alternative to revisional surgery for patients experiencing insufficient weight loss (IWL) or weight regain (WR) after bariatric surgery. Tirzepatide, the newest GLP-1 \/GIP agonist, has shown superior results compared to liraglutide and semaglutide. However, more long-term randomized controlled trials are needed to confirm these findings and further assess its effectiveness. Despite this, GLP-1 agonists consistently demonstrate significant weight loss and cardiometabolic improvements when compared to placebo or lifestyle modifications, making them a valuable treatment option for post-bariatric surgery patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00423-025-03831-4","type":"journal-article","created":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:29:34Z","timestamp":1760077774000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["GLP-1 receptor agonists as an adjunct to bariatric surgery for weight loss and metabolic outcome improvement: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"410","author":[{"given":"Yee Wen","family":"Tan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengge","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivakumar","family":"Gananadha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,10]]},"reference":[{"key":"3831_CR1","doi-asserted-by":"publisher","first-page":"e40364","DOI":"10.1097\/md.0000000000040364","volume":"103","author":"FA Raza","year":"2024","unstructured":"Raza FA, Altaf R, Bashir T et al (2024) Effect of GLP-1 receptor agonists on weight and cardiovascular outcomes: a review. Medicine 103:e40364\u2013e40364. https:\/\/doi.org\/10.1097\/md.0000000000040364","journal-title":"Medicine"},{"key":"3831_CR2","doi-asserted-by":"publisher","first-page":"S191","DOI":"10.2337\/dc23-s011","volume":"46","author":"NA ElSayed","year":"2022","unstructured":"ElSayed NA, Aleppo G, Aroda VR et al (2022) 11. Chronic kidney disease and risk management: Standards of care in Diabetes\u20142023. Diabetes Care 46:S191\u2013S202. https:\/\/doi.org\/10.2337\/dc23-s011","journal-title":"Diabetes Care"},{"key":"3831_CR3","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1016\/j.jdiacomp.2017.08.005","volume":"31","author":"E Gourgari","year":"2017","unstructured":"Gourgari E, Wilhelm EE, Hassanzadeh H et al (2017) A comprehensive review of the FDA-approved labels of diabetes drugs: indications, safety, and emerging cardiovascular safety data. J Diabetes Complications 31:1719\u20131727. https:\/\/doi.org\/10.1016\/j.jdiacomp.2017.08.005","journal-title":"J Diabetes Complications"},{"key":"3831_CR4","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","volume":"63","author":"Y-S Lee","year":"2014","unstructured":"Lee Y-S, Jun H-S (2014) Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 63:9\u201319. https:\/\/doi.org\/10.1016\/j.metabol.2013.09.010","journal-title":"Metabolism"},{"key":"3831_CR5","doi-asserted-by":"publisher","first-page":"10449","DOI":"10.3390\/ijms241310449","volume":"24","author":"MS Popoviciu","year":"2023","unstructured":"Popoviciu MS, P\u0103duraru L, Yahya G et al (2023) Emerging role of GLP-1 agonists in obesity: a comprehensive review of randomised controlled trials. Int J Mol Sci 24:10449\u201310449. https:\/\/doi.org\/10.3390\/ijms241310449","journal-title":"Int J Mol Sci"},{"key":"3831_CR6","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/s41366-024-01473-y","volume":"49","author":"E Melson","year":"2024","unstructured":"Melson E, Ashraf U, Papamargaritis D, Davies MJ (2024) What is the pipeline for future medications for obesity? Int J Obes 49:433\u2013451. https:\/\/doi.org\/10.1038\/s41366-024-01473-y","journal-title":"Int J Obes"},{"key":"3831_CR7","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s11695-021-05426-6","volume":"31","author":"FF Horber","year":"2021","unstructured":"Horber FF, Steffen R (2021) Reversal of long-term weight regain after Roux-en-Y gastric bypass using liraglutide or surgical revision. A prospective study. Obes Surg 31:93\u2013100. https:\/\/doi.org\/10.1007\/s11695-021-05426-6","journal-title":"Obes Surg"},{"key":"3831_CR8","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"3831_CR9","doi-asserted-by":"publisher","first-page":"i4919","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"key":"3831_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-5-13","author":"SP Hozo","year":"2005","unstructured":"Hozo SP, Djulbegovic B, Hozo I (2005) Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. https:\/\/doi.org\/10.1186\/1471-2288-5-13","journal-title":"BMC Med Res Methodol"},{"key":"3831_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12593","author":"A Lautenbach","year":"2023","unstructured":"Lautenbach A, Kantowski T, Wagner J et al (2023) Sustained weight loss with semaglutide once weekly in patients without type 2 diabetes and post-bariatric treatment failure. Clin Obes. https:\/\/doi.org\/10.1111\/cob.12593","journal-title":"Clin Obes"},{"key":"3831_CR12","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-022-06211-9","author":"A Lautenbach","year":"2022","unstructured":"Lautenbach A, Wernecke M, Huber TB et al (2022) The potential of semaglutide once-weekly in patients without type 2 diabetes with weight regain or insufficient weight loss after bariatric surgery\u2014a retrospective analysis. Obes Surg. https:\/\/doi.org\/10.1007\/s11695-022-06211-9","journal-title":"Obes Surg"},{"key":"3831_CR13","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-04850-4","author":"U Thakur","year":"2020","unstructured":"Thakur U, Bhansali A, Gupta R, Rastogi A (2020) Liraglutide augments weight loss after laparoscopic sleeve gastrectomy: a randomised, double-blind, placebo-control study. Obes Surg. https:\/\/doi.org\/10.1007\/s11695-020-04850-4","journal-title":"Obes Surg"},{"key":"3831_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/s2213-8587(19)30157-3","volume":"7","author":"AD Miras","year":"2019","unstructured":"Miras AD, P\u00e9rez-Pevida B, Aldhwayan M et al (2019) Adjunctive liraglutide treatment in patients with persistent or recurrent type 2 diabetes after metabolic surgery (GRAVITAS): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 7:549\u2013559. https:\/\/doi.org\/10.1016\/s2213-8587(19)30157-3","journal-title":"Lancet Diabetes Endocrinol"},{"key":"3831_CR15","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1001\/jamasurg.2023.2930","volume":"158","author":"J Mok","year":"2023","unstructured":"Mok J, Adeleke MO, Brown A et al (2023) Safety and efficacy of liraglutide, 3.0 mg, once daily vs placebo in patients with poor weight loss following metabolic surgery: the BARI-OPTIMISE randomized clinical trial. JAMA Surg 158:1003\u20131011. https:\/\/doi.org\/10.1001\/jamasurg.2023.2930","journal-title":"JAMA Surg"},{"key":"3831_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s11695-023-07053-9","volume":"34","author":"F Vinciguerra","year":"2024","unstructured":"Vinciguerra F, Di Stefano C, Baratta R et al (2024) Efficacy of high-dose liraglutide 3.0 mg in patients with poor response to bariatric surgery: real-world experience and updated meta-analysis. Obes Surg 34:303\u2013309. https:\/\/doi.org\/10.1007\/s11695-023-07053-9","journal-title":"Obes Surg"},{"key":"3831_CR17","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1007\/s11695-021-05884-y","volume":"32","author":"W Elhag","year":"2022","unstructured":"Elhag W, El Ansari W (2022) Effectiveness and safety of liraglutide in managing inadequate weight loss and weight regain after primary and revisional bariatric surgery: anthropometric and cardiometabolic outcomes. Obes Surg 32:1005\u20131015. https:\/\/doi.org\/10.1007\/s11695-021-05884-y","journal-title":"Obes Surg"},{"key":"3831_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00423-023-02805-8","author":"JRM Colbourne","year":"2023","unstructured":"Colbourne JRM, Fisher OM, Mo S et al (2023) The role of adjuvant pharmacotherapy with liraglutide for patients with inadequate weight loss following bariatric surgery. Langenbecks Arch Surg. https:\/\/doi.org\/10.1007\/s00423-023-02805-8","journal-title":"Langenbecks Arch Surg"},{"key":"3831_CR19","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1590\/s0100-69912013000300005","volume":"40","author":"D Pajecki","year":"2013","unstructured":"Pajecki D, Halpern A, Cercato C et al (2013) Short-term use of liraglutide in the management of patients with weight regain after bariatric surgery. Revista do col\u00e9gio. Brasileiro De Cirurgi\u00f5es 40:191\u2013195. https:\/\/doi.org\/10.1590\/s0100-69912013000300005","journal-title":"Brasileiro De Cirurgi\u00f5es"},{"issue":"7","key":"3831_CR20","doi-asserted-by":"publisher","first-page":"2775","DOI":"10.1007\/s40519-022-01403-9","volume":"27","author":"F Muratori","year":"2022","unstructured":"Muratori F, Vignati F, Di Sacco G et al (2022) Efficacy of liraglutide 3.0 mg treatment on weight loss in patients with weight regain after bariatric surgery. Eat Weight Disord 27(7):2775\u20132781. https:\/\/doi.org\/10.1007\/s40519-022-01403-9","journal-title":"Eat Weight Disord"},{"key":"3831_CR21","doi-asserted-by":"publisher","first-page":"4216","DOI":"10.1007\/s11695-021-05535-2","volume":"31","author":"MA Rubio","year":"2021","unstructured":"Rubio MA, Ramos-Lev\u00ed AM (2021) Initial experience with alternate-day liraglutide for weight regain following bariatric surgery. Obes Surg 31:4216\u20134218. https:\/\/doi.org\/10.1007\/s11695-021-05535-2","journal-title":"Obes Surg"},{"key":"3831_CR22","doi-asserted-by":"publisher","first-page":"3553","DOI":"10.1007\/s11695-018-3393-7","volume":"28","author":"P Rye","year":"2018","unstructured":"Rye P, Modi R, Cawsey S, Sharma AM (2018) Efficacy of high-dose liraglutide as an adjunct for weight loss in patients with prior bariatric surgery. Obes Surg 28:3553\u20133558. https:\/\/doi.org\/10.1007\/s11695-018-3393-7","journal-title":"Obes Surg"},{"key":"3831_CR23","doi-asserted-by":"publisher","DOI":"10.1111\/cob.12323","author":"S Wharton","year":"2019","unstructured":"Wharton S, Kuk JL, Luszczynski M et al (2019) Liraglutide 3.0 mg for the management of insufficient weight loss or excessive weight regain post-bariatric surgery. Clin Obes. https:\/\/doi.org\/10.1111\/cob.12323","journal-title":"Clin Obes"},{"key":"3831_CR24","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1016\/j.soard.2016.02.013","volume":"12","author":"JJ Gorgojo-Mart\u00ednez","year":"2016","unstructured":"Gorgojo-Mart\u00ednez JJ, Feo-Ortega G, Serrano-Moreno C (2016) Effectiveness and tolerability of liraglutide in patients with type 2 diabetes mellitus and obesity after bariatric surgery. Surg Obes Relat Dis 12:1856\u20131863. https:\/\/doi.org\/10.1016\/j.soard.2016.02.013","journal-title":"Surg Obes Relat Dis"},{"key":"3831_CR25","doi-asserted-by":"publisher","unstructured":"Jamal M, Qasem W, Hamshari F et al (2023) Effectiveness and tolerability of liraglutide for the management of weight regain following sleeve gastrectomy. Obes Sci Pract 10. https:\/\/doi.org\/10.1002\/osp4.706","DOI":"10.1002\/osp4.706"},{"key":"3831_CR26","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-023-06484-8","author":"AB Jensen","year":"2023","unstructured":"Jensen AB, Renstr\u00f6m F, Acz\u00e9l S et al (2023) Efficacy of the glucagon-like peptide-1 receptor agonists liraglutide and semaglutide for the treatment of weight regain after bariatric surgery: a retrospective observational study. Obes Surg. https:\/\/doi.org\/10.1007\/s11695-023-06484-8","journal-title":"Obes Surg"},{"key":"3831_CR27","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s11695-024-07137-0","volume":"34","author":"M Jamal","year":"2024","unstructured":"Jamal M, Alhashemi M, Dsouza C et al (2024) Semaglutide and tirzepatide for the management of weight recurrence after sleeve gastrectomy: a retrospective cohort study. Obes Surg 34:1324\u20131332. https:\/\/doi.org\/10.1007\/s11695-024-07137-0","journal-title":"Obes Surg"},{"key":"3831_CR28","doi-asserted-by":"publisher","DOI":"10.1002\/oby.23736","author":"Natia Murvelashvili","year":"2023","unstructured":"Murvelashvili Natia, Xie L, Schellinger JN et al (2023) Effectiveness of semaglutide versus liraglutide for treating post-metabolic and bariatric surgery weight recurrence. Obesity. https:\/\/doi.org\/10.1002\/oby.23736","journal-title":"Obesity"},{"key":"3831_CR29","doi-asserted-by":"publisher","DOI":"10.1007\/s11695-020-05160-5","author":"W El Ansari","year":"2021","unstructured":"El Ansari W, Elhag W (2021) Weight regain and insufficient weight loss after bariatric surgery: definitions, prevalence, mechanisms, predictors, prevention and management strategies, and knowledge gaps\u2014a scoping review. Obes Surg. https:\/\/doi.org\/10.1007\/s11695-020-05160-5","journal-title":"Obes Surg"},{"key":"3831_CR30","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1097\/SLA.0b013e3180caa3e3","volume":"246","author":"CW le Roux","year":"2007","unstructured":"le Roux CW, Welbourn R, Werling M et al (2007) Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric bypass. Ann Surg 246:780\u2013785. https:\/\/doi.org\/10.1097\/SLA.0b013e3180caa3e3","journal-title":"Ann Surg"},{"key":"3831_CR31","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1007\/s11695-023-07028-w","volume":"34","author":"J Siren Nymo, Lundanes","year":"2023","unstructured":"Siren Nymo, Lundanes J, Eriksen K et al (2023) Suboptimal weight loss 13 years after Roux-en-Y gastric bypass is associated with blunted appetite response. Obes Surg 34:592\u2013601. https:\/\/doi.org\/10.1007\/s11695-023-07028-w","journal-title":"Obes Surg"},{"key":"3831_CR32","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-024-02029-0","author":"Lud\u011bk Horv\u00e1th","year":"2024","unstructured":"Horv\u00e1th Lud\u011bk, Mr\u00e1z Milo\u0161, Jude EB, Haluz\u00edk M (2024) Pharmacotherapy as an augmentation to bariatric surgery for obesity. Drugs. https:\/\/doi.org\/10.1007\/s40265-024-02029-0","journal-title":"Drugs"},{"key":"3831_CR33","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1056\/NEJMoa2032183","volume":"384","author":"JPH Wilding","year":"2021","unstructured":"Wilding JPH, Batterham RL, Calanna S (2021) Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 384:989\u20131002. https:\/\/doi.org\/10.1056\/NEJMoa2032183","journal-title":"N Engl J Med"},{"key":"3831_CR34","doi-asserted-by":"publisher","first-page":"2626","DOI":"10.1111\/dom.15148","volume":"25","author":"CW le Roux","year":"2023","unstructured":"le Roux CW, Hankosky ER, Wang D et al (2023) Tirzepatide 10 and 15 mg compared with semaglutide 2.4 mg for the treatment of obesity: an indirect treatment comparison. Diabetes Obes Metab 25:2626\u20132633. https:\/\/doi.org\/10.1111\/dom.15148","journal-title":"Diabetes Obes Metab"},{"key":"3831_CR35","doi-asserted-by":"publisher","unstructured":"Iorga R, Bacalbasa N, Carsote M et al (2020) Metabolic and cardiovascular benefits of GLP-1 agonists, besides the hypoglycemic effect (Review). Experimental Therapeutic Med 20. https:\/\/doi.org\/10.3892\/etm.2020.8714","DOI":"10.3892\/etm.2020.8714"},{"key":"3831_CR36","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.122.029282","author":"ED Michos","year":"2023","unstructured":"Michos ED, Lopez-Jimenez F, Gulati M (2023) Role of glucagon-like peptide\u20101 receptor agonists in achieving weight loss and improving cardiovascular outcomes in people with overweight and obesity. J Am Heart Assoc. https:\/\/doi.org\/10.1161\/jaha.122.029282","journal-title":"J Am Heart Assoc"},{"key":"3831_CR37","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1900\/rds.2014.11.202","volume":"11","author":"TD Filippatos","year":"2015","unstructured":"Filippatos TD, Panagiotopoulou TV, Elisaf MS (2015) Adverse effects of GLP-1 receptor agonists. Rev Diabet Stud 11:202\u2013230. https:\/\/doi.org\/10.1900\/rds.2014.11.202","journal-title":"Rev Diabet Stud"},{"key":"3831_CR38","doi-asserted-by":"publisher","first-page":"g2366","DOI":"10.1136\/bmj.g2366","volume":"348","author":"L Li","year":"2014","unstructured":"Li L, Shen J, Bala MM et al (2014) Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies. BMJ 348:g2366\u2013g2366. https:\/\/doi.org\/10.1136\/bmj.g2366","journal-title":"BMJ"},{"key":"3831_CR39","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/dom.12386","volume":"17","author":"T Wang","year":"2014","unstructured":"Wang T, Wang F, Gou Z et al (2014) Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1 324 515 patients from observational studies. Diabetes Obes Metab 17:32\u201341. https:\/\/doi.org\/10.1111\/dom.12386","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"3831_CR40","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1001\/jama.2021.23619","volume":"327","author":"DM Rubino","year":"2022","unstructured":"Rubino DM, Greenway FL, Khalid U et al (2022) Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults with overweight or obesity without diabetes. JAMA 327:138. https:\/\/doi.org\/10.1001\/jama.2021.23619","journal-title":"JAMA"},{"key":"3831_CR41","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2107519","author":"JP Fr\u00edas","year":"2021","unstructured":"Fr\u00edas JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med. https:\/\/doi.org\/10.1056\/nejmoa2107519","journal-title":"N Engl J Med"},{"key":"3831_CR42","doi-asserted-by":"publisher","DOI":"10.1007\/s13304-024-01828-0","author":"M Patricia","year":"2024","unstructured":"Patricia M, Reyes D, Susana I et al (2024) Liraglutide effectiveness in preoperative weight-loss for patients with severe obesity undergoing bariatric-metabolic surgery. Update Surg. https:\/\/doi.org\/10.1007\/s13304-024-01828-0","journal-title":"Update Surg"}],"container-title":["Langenbeck's Archives of Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00423-025-03831-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00423-025-03831-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:49:20Z","timestamp":1781614160000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00423-025-03831-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,10]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3831"],"URL":"https:\/\/doi.org\/10.1007\/s00423-025-03831-4","relation":{},"ISSN":["1435-2451"],"issn-type":[{"value":"1435-2451","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,10]]},"assertion":[{"value":"3 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"295"}}